Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONL1204 in Geographic Atrophy Associated With AMD
NCT06659445Phase 2Recruiting
- Sponsor
- ONL Therapeutics
- Start
- Oct 2025
- Primary completion
- Nov 2028
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of xelafaslatide in geographic atrophy (GA), sponsored by ONL Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
xelafaslatide
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06659445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659445.